Topkan Erkan, Ozdemir Yurday, Guler Ozan Cem, Kucuk Ahmet, Besen Ali Ayberk, Mertsoylu Huseyin, Sezen Duygu, Akdemir Eyub Yasar, Sezer Ahmet, Bolukbasi Yasemin, Pehlivan Berrin, Selek Ugur
Baskent University Medical Faculty, Department of Radiation Oncology, Adana, Turkey.
Mersin City Hospital, Radiation Oncology Clinics, Mersin, Turkey.
J Oncol. 2020 Sep 4;2020:7083149. doi: 10.1155/2020/7083149. eCollection 2020.
We retrospectively compared the incidence of isolated elective nodal failure (IENF) and toxicity rates and survival outcomes after elective nodal irradiation (ENI) versus involved-field RT (IFRT) by employing the propensity score matching (PSM) methodology in stage IIIB/C inoperable non-small-cell lung cancer (NSCLC) patients treated with definitive concurrent chemoradiotherapy (C-CRT).
Our PSM examination included 1048 stage IIIB/C NSCLC patients treated with C-CRT from January 2007 to December 2016: a total dose of 66 Gy (2 Gy/fraction) radiotherapy and 1-3 cycles of platinum-based doublet chemotherapy concurrently. The primary and secondary endpoints were the IENF and toxicity rates and survival outcomes after ENI versus IFRT, respectively. Propensity scores were calculated for each group to adjust for confounding variables and facilitate well-balanced comparability by creating 1 : 1 matched study groups.
The median follow-up was 26.4 months for the whole study accomplice. The PSM analysis unveiled 1 : 1 matched 646 patients for the ENI ( = 323) and IFRT ( = 323) cohorts. Intergroup comparisons discovered that the 5-year isolated ENF incidence rates (3.4% versus 4.3%; =0.52) and median overall survival (25.2 versus 24.6 months; =0.69), locoregional progression-free survival (15.3 versus 15.1 months; =0.52), and progression-free survival (11.7 versus 11.2 months; =0.57) durations were similar between the ENI and IFRT cohorts, separately. However, acute grade 3-4 leukopenia (=0.0012), grade 3 nausea-vomiting (=0.006), esophagitis (=0.003), pneumonitis (=0.002), late grade 3-4 esophageal toxicity (=0.038), and the need for hospitalization ( < 0.001) were all significantly higher in the ENI than in the IFRT group, respectively.
Results of the present large-scale PSM cohort established the absence of meaningful IENF or survival differences between the IFRT and ENI cohorts and, consequently, counseled the IFRT as the elected RT technique for such patients since ENI increased the toxicity rates.
我们采用倾向评分匹配(PSM)方法,回顾性比较了接受根治性同步放化疗(C-CRT)的IIIB/C期不可切除非小细胞肺癌(NSCLC)患者中,选择性淋巴结照射(ENI)与累及野放疗(IFRT)后孤立性选择性淋巴结失败(IENF)的发生率、毒性率和生存结果。
我们的PSM检查纳入了2007年1月至2016年12月期间接受C-CRT治疗的1048例IIIB/C期NSCLC患者:放疗总剂量为66 Gy(2 Gy/分次),同时进行1-3周期铂类双联化疗。主要和次要终点分别是ENI与IFRT后的IENF、毒性率和生存结果。计算每组的倾向评分,以调整混杂变量,并通过创建1:1匹配的研究组促进均衡可比性。
整个研究队列的中位随访时间为26.4个月。PSM分析显示,ENI组(n = 323)和IFRT组(n = 323)有1:1匹配的646例患者。组间比较发现,ENI组和IFRT组的5年孤立性ENF发生率(3.4%对4.3%;P = 0.52)、中位总生存期(25.2个月对24.6个月;P = 0.69)、局部区域无进展生存期(15.3个月对15.1个月;P = 0.52)和无进展生存期(11.7个月对11.2个月;P = 0.57)持续时间相似。然而,ENI组的急性3-4级白细胞减少(P = 0.0012)、3级恶心呕吐(P = 0.006)、食管炎(P = 0.003)、肺炎(P = 0.002)、晚期3-4级食管毒性(P = 0.038)以及住院需求(P < 0.001)均显著高于IFRT组。
本大规模PSM队列研究结果表明,IFRT组和ENI组之间不存在有意义的IENF或生存差异,因此,鉴于ENI增加了毒性率,建议将IFRT作为此类患者的首选放疗技术。